REGULATORY

Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain

May 13, 2021
An all-important reimbursement policy panel on May 12 supported the application of re-pricing for Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) under the quarterly price review scheme. Three other I/O drug makers, which also face reductions under the rule, have lodged…

To read the full story

Related Article

REGULATORY

By Philip Carrigan

In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…

By Ken Yoshino

The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…

By Ken Yoshino

Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…

By Yoshinori Sagehashi

Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…